Jeffrey Hessekiel - Mar 1, 2023 Form 4 Insider Report for EXELIXIS, INC. (EXEL)

Role
EVP, General Counsel & Sec
Signature
/s/ Nina Ayer, Attorney in Fact
Stock symbol
EXEL
Transactions as of
Mar 1, 2023
Transactions value $
-$923,085
Form type
4
Date filed
3/3/2023, 06:59 PM
Previous filing
Feb 17, 2023
Next filing
Apr 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXEL Common Stock Options Exercise $411K +27.9K +4.82% $14.74 606K Mar 1, 2023 Direct F1
transaction EXEL Common Stock Sale -$1.33M -77.9K -12.86% $17.13 528K Mar 1, 2023 Direct F2, F3
holding EXEL Common Stock 999 Mar 1, 2023 By 401(k) F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXEL Option (right to buy) Options Exercise $0 -27.9K -28.57% $0.00 69.6K Mar 1, 2023 Common Stock 27.9K $14.74 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 125,202 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2022.
F3 Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.28. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4 Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of February 28, 2023.
F5 The option, representing the right to purchase a total of 97,500 shares of Exelixis, Inc. common stock, became fully exercisable on September 22, 2020.